Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Dose-response relationships in healthy young and middle-aged adults
Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results Best For Recommendations# Currently Available Treatment# Recommendation : Tirzepatide Reason : FDA-approved and commercially available as Mounjaro/Zepbound with established dosing protocols and post-market safety data Maximum Weight Loss Potential# Recommendation : Retatrutide Reason : Phase 2 data showed 24.2% weight loss at 48 weeks, exceeding tirzepatide's results, though Phase 3 confirmation is pending Non-Alcoholic Fatty Liver Disease# Recommendation : Retatrutide Reason : Glucagon receptor agonism directly promotes hepatic fat oxidation, showing up to 82% liver fat reduction in trials Type 2 Diabetes Management# Recommendation : Tirzepatide Reason : Proven HbA1c reduction with FDA approval specifically for glycemic control in type 2 diabetes Further Reading# Which Is Better For
Ongoing monitoring
Anecdotal reports from research settings suggest mild stimulant-like effects in some individuals
L.GerwigU
US$ 26.45
US$ 29.57
US$ 27.06